Cancer metastasis

Cancer therapy targeting cancer stem cells in chronic myelogenous leukemia (CML) and other metastatic cancers: Misoprostol, an FDA-approved EP4 agonist and abortion-promoting drug, increases the expression of tumor suppressor genes, such as IGFBP3, PIAS3, p53, and TA-p73/p63, targets CML leukemic stem cells, confers protection against CML and prolongs survival, via up-regulation of its target gene, 6/November/2018,11.28 pm
Cancer therapy targeting cancer stem cells in chronic myelogenous leukemia (CML) and other metastatic cancers: Misoprostol, an FDA-approved EP4 agonist and abortion-promoting drug, increases the expression of tumor suppressor genes, such as IGFBP3, PIAS3, p53, and TA-p73/p63, targets CML leukemic stem cells, confers protection against CML and prolongs survival, via up-regulation of its target gene, 6/November/2018,11.28 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Department of Microbiology and Immunology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA shows that “Prostaglandin E1 and…

read more

Probiotic-based therapy for cancer metastasis: Probiotic Lactobacillus Rhamnosus inhibits the expression of IL-6/8, decreases the expression of downstream molecules WASF3 and Arp2/3, suppresses tumor cell migration, reduces metastasis and prolongs survival via upregulation of its target gene, 6/November/2017, 11.06 pm
Probiotic-based therapy for cancer metastasis: Probiotic Lactobacillus Rhamnosus inhibits the expression of IL-6/8, decreases the expression of downstream molecules WASF3 and Arp2/3, suppresses tumor cell migration, reduces metastasis and prolongs survival via upregulation of its target gene, 6/November/2017, 11.06 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, Baltimore, Maryland 21218, USA; Johns Hopkins Physical Sciences-Oncology Center, The Johns Hopkins University,…

read more

Probiotic-based anti-cancer therapy for CyclinD3-CDK6 overexpressing cancers:Probiotic Lactobacillus Rhamnosus inhibits the activity of glycolytic enzymes 6-phosphofructokinase and pyruvate kinase M2, decreases antioxidants NADPH and glutathione levels, increases reactive oxygen species levels, promotes apoptosis, and inhibits the progression of CyclinD3-CDK6 overexpressing cancers via down-regulation of its target gene, 6/November/2018,10.27 pm
Probiotic-based anti-cancer therapy for CyclinD3-CDK6 overexpressing cancers:Probiotic Lactobacillus Rhamnosus inhibits the activity of glycolytic enzymes 6-phosphofructokinase and pyruvate kinase M2, decreases antioxidants NADPH and glutathione levels, increases reactive oxygen species levels, promotes apoptosis, and inhibits the progression of CyclinD3-CDK6 overexpressing cancers via down-regulation of its target gene, 6/November/2018,10.27 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; and Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA shows that “The…

read more

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced ovarian cancer and other metastatic cancers: A pharmaceutical mixture encompassing Olaparib, an FDA-approved poly (adenosine diphosphate-ribose) polymerase inhibitor, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PDCD4, TIMP3, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 6/November/2018, 12.27 am
Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced ovarian cancer and other metastatic cancers: A pharmaceutical mixture encompassing Olaparib, an FDA-approved poly (adenosine diphosphate-ribose) polymerase inhibitor, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PDCD4, TIMP3, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 6/November/2018, 12.27 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Stephenson Cancer Center at the University of Oklahoma, Oklahoma City (K.M.); University of Milan-Bicocca, European Institute of Oncology Istituto di Ricovero e…

read more

Probiotic-based therapy for PTEN-deficient cancer: Probiotic Lactobacillus Rhamnosus decreases the expression of CHD1, increases the expression of a number of tumor suppressor genes, inhibits pro-survival TNF-NF-kB gene network, and suppresses tumorigenesis of PTEN-deficient cancers, 5/November/2018, 11.59 pm
Probiotic-based therapy for PTEN-deficient cancer: Probiotic Lactobacillus Rhamnosus decreases the expression of CHD1, increases the expression of a number of tumor suppressor genes, inhibits pro-survival TNF-NF-kB gene network, and suppresses tumorigenesis of PTEN-deficient cancers, 5/November/2018, 11.59 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA shows that “Synthetic essentiality of chromatin remodelling…

read more

Awakening the sleeping/cancer-protecting angels in mutant p53 human tumors: Sulindac (brand name: Clinoril), a nonsteroidal anti-inflammatory drug (NSAID) used in the treatment of acute and chronic inflammatory conditions,  increases the expression of tumor suppressors genes, such as PDCD4, CADM1/2,  p53, TAp63, TAp73, INK4a, and others, and induces regression of p53-mutated human cancers and other cancers, via up-regulation of its target gene, 5/November/2018, 11.48 pm
Awakening the sleeping/cancer-protecting angels in mutant p53 human tumors: Sulindac (brand name: Clinoril), a nonsteroidal anti-inflammatory drug (NSAID) used in the treatment of acute and chronic inflammatory conditions,  increases the expression of tumor suppressors genes, such as PDCD4, CADM1/2,  p53, TAp63, TAp73, INK4a, and others, and induces regression of p53-mutated human cancers and other cancers, via up-regulation of its target gene, 5/November/2018, 11.48 pm 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance:  Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53…

read more
Start Typing